These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 30398559)

  • 21. Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults.
    Le P; Rothberg MB
    JAMA Intern Med; 2018 Feb; 178(2):248-258. PubMed ID: 29297049
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preventing herpes zoster through vaccination.
    Gelb LD
    Ophthalmology; 2008 Feb; 115(2 Suppl):S35-8. PubMed ID: 18243932
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of the potential public health impact of Herpes Zoster vaccination in Germany.
    Curran D; Van Oorschot D; Varghese L; Oostvogels L; Mrkvan T; Colindres R; von Krempelhuber A; Anastassopoulou A
    Hum Vaccin Immunother; 2017 Oct; 13(10):2213-2221. PubMed ID: 28708959
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of vaccination against herpes zoster in adults aged over 60 years in Belgium.
    Bilcke J; Marais C; Ogunjimi B; Willem L; Hens N; Beutels P
    Vaccine; 2012 Jan; 30(3):675-84. PubMed ID: 22120193
    [TBL] [Abstract][Full Text] [Related]  

  • 25. What are the new vaccination recommendations for herpes zoster?
    Mospan CM; Colvin N
    JAAPA; 2018 Oct; 31(10):14-15. PubMed ID: 30252758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The public health and the question of the "best vaccine".
    Tafuri S; Bianchi FP; Stefanizzi P
    Vaccine; 2022 Jun; 40(28):3813-3814. PubMed ID: 35644671
    [No Abstract]   [Full Text] [Related]  

  • 27. Cost-effectiveness of vaccination against herpes zoster and postherpetic neuralgia: a critical review.
    Kawai K; Preaud E; Baron-Papillon F; Largeron N; Acosta CJ
    Vaccine; 2014 Mar; 32(15):1645-53. PubMed ID: 24534737
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Declining Effectiveness of Herpes Zoster Vaccine in Adults Aged ≥60 Years.
    Tseng HF; Harpaz R; Luo Y; Hales CM; Sy LS; Tartof SY; Bialek S; Hechter RC; Jacobsen SJ
    J Infect Dis; 2016 Jun; 213(12):1872-5. PubMed ID: 26908728
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
    Hornberger J; Robertus K
    Ann Intern Med; 2006 Sep; 145(5):317-25. PubMed ID: 16954357
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Update on vaccine-preventable diseases: are adults in your community adequately protected?
    Schaffner W
    J Fam Pract; 2008 Apr; 57(4 Suppl):S1-11; quiz S12. PubMed ID: 18655764
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Herpes Zoster Vaccine: Time for a Boost?
    Reddy KP
    J Gen Intern Med; 2017 Feb; 32(2):145-147. PubMed ID: 27730484
    [No Abstract]   [Full Text] [Related]  

  • 32. Cost-effectiveness of varicella vaccine against herpes zoster and post-herpetic neuralgia for elderly in Japan.
    Hoshi SL; Kondo M; Okubo I
    Vaccine; 2017 May; 35(24):3264-3271. PubMed ID: 28479176
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In adults ≥ 70 years of age, an adjuvanted herpes zoster subunit vaccine reduced herpes zoster at a mean 3.7 years.
    Sacks HS
    Ann Intern Med; 2017 Jan; 166(2):JC5. PubMed ID: 28114461
    [No Abstract]   [Full Text] [Related]  

  • 34. Herpes zoster subunit vaccine for the prevention of herpes zoster.
    Symoniak MR; Farrokh P; Gandhi MA; Slish JC
    Am J Health Syst Pharm; 2018 Jun; 75(12):861-869. PubMed ID: 29880523
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Herpes zoster vaccine: A health economic evaluation for Switzerland.
    Blank PR; Ademi Z; Lu X; Szucs TD; Schwenkglenks M
    Hum Vaccin Immunother; 2017 Jul; 13(7):1495-1504. PubMed ID: 28481678
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of an Adjuvanted Recombinant Zoster Vaccine in older adults in the United States.
    Curran D; Patterson B; Varghese L; Van Oorschot D; Buck P; Carrico J; Hicks K; Lee B; Yawn B
    Vaccine; 2018 Aug; 36(33):5037-5045. PubMed ID: 30017145
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: Results of a phase III, randomized, open-label, multicenter study.
    Lal H; Poder A; Campora L; Geeraerts B; Oostvogels L; Vanden Abeele C; Heineman TC
    Vaccine; 2018 Jan; 36(1):148-154. PubMed ID: 29174683
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Herpes Zoster Vaccination: Controversies and Common Clinical Questions.
    Van Epps P; Schmader KE; Canaday DH
    Gerontology; 2016; 62(2):150-4. PubMed ID: 26184711
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Retrospective financial analysis of a herpes zoster vaccination program from an independent community pharmacy perspective.
    Wood HM; McDonough RP; Doucette WR
    J Am Pharm Assoc (2003); 2009; 49(1):12-7. PubMed ID: 19196591
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Herpes zoster and vaccination: a clinical review.
    Adams EN; Parnapy S; Bautista P
    Am J Health Syst Pharm; 2010 May; 67(9):724-7. PubMed ID: 20410546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.